Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKesson
Boehringer Ingelheim
Dow
Johnson and Johnson

Last Updated: February 1, 2023

Patent: 10,047,096


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 10,047,096
Title:Substituted pyridobenzodiazepinone-derivatives and use thereof
Abstract: The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
Inventor(s): Schall; Andreas (Wuppertal, DE), Klar; Jurgen (Wuppertal, DE), Lobell; Mario (Wuppertal, DE), Schirok; Hartmut (Langenfeld, DE), Telser; Joachim (Wuppertal, DE), Muller; Steffen (Essen, DE), Brohm; Dirk (Mettmann, DE), Briem; Hans (Berlin, DE), Jori en; Hannah (Heiligenhaus, DE), Keldenich; Joerg (Berlin, DE), Bottger; Michael (Wuppertal, DE), Von Degenfeld; Georges (Leverkusen, DE), Schlange; Thomas (Haan, DE), Bomer; Ulf (Glienicke, DE), Lindner; Niels (Wuppertal, DE), Eilken; Hanna (Wuppertal, DE), Hristodorov; Dmitrij (Wuppertal, DE), Wasnaire; Pierre (Dusseldorf, DE), Gericke; Kersten Matthias (Wuppertal, DE), Barfacker; Lars (Dusseldorf, DE)
Assignee: Bayer Pharma Aktiengesellschaft (Berlin, DE)
Application Number:15/529,043
Patent Claims:see list of patent claims

Details for Patent 10,047,096

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 See Plans and Pricing 2034-11-25
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 06/30/2006 See Plans and Pricing 2034-11-25
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 08/10/2012 See Plans and Pricing 2034-11-25
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 10/13/2016 See Plans and Pricing 2034-11-25
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 03/20/2018 See Plans and Pricing 2034-11-25
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 11/18/2011 See Plans and Pricing 2034-11-25
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Johnson and Johnson
Moodys
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.